These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 8817800)
41. [Meta-analysis and therapeutic decision making]. Uhari M Duodecim; 1993; 109(7):560-1. PubMed ID: 8062725 [No Abstract] [Full Text] [Related]
42. New methodology in clinical trials. Healy MJ Biometrics; 1978 Dec; 34(4):709-12. PubMed ID: 749953 [No Abstract] [Full Text] [Related]
43. Giving medicine a fair trial. Blanket enthusiasm for trials won't help. Szebik I BMJ; 2000 Dec; 321(7275):1530-1. PubMed ID: 11118192 [No Abstract] [Full Text] [Related]
44. Meta-analysis of clinical trials: summary of an international conference. Boissel JP; Sacks HS; Leizorovicz A; Blanchard J; Panak E; Peyrieux JC Eur J Clin Pharmacol; 1988; 34(6):535-8. PubMed ID: 3169107 [TBL] [Abstract][Full Text] [Related]
45. Fundamentals of planning a clinical trial. II. Ozick J J Oral Ther Pharmacol; 1967 Jan; 3(4):300-7. PubMed ID: 5337865 [No Abstract] [Full Text] [Related]
46. Making decisions based on group designs and meta-analysis. Norton BJ; Strube MJ Phys Ther; 1989 Jul; 69(7):594-600. PubMed ID: 2662228 [No Abstract] [Full Text] [Related]
47. Prevention trials. Kessler L; Taylor P Med Decis Making; 1989; 9(1):1-2. PubMed ID: 2643016 [No Abstract] [Full Text] [Related]
48. Things to avoid in meta-analysis. Szczesniak A; Gorny B; Kowalewski M; Kolodziejczak M; Kotlarek N Eur J Prev Cardiol; 2013 Jun; 20(3):513. PubMed ID: 23529609 [No Abstract] [Full Text] [Related]
49. The planning of clinical studies: bias and precision. Debanne SM Gastrointest Endosc; 2000 Dec; 52(6):821-2. PubMed ID: 11115938 [No Abstract] [Full Text] [Related]
50. Controlled trials and meta-analyses can help resolve disagreements among orthopaedic surgeons. Chalmers IG; Collins RE; Dickersin K J Bone Joint Surg Br; 1992 Sep; 74(5):641-3. PubMed ID: 1527105 [No Abstract] [Full Text] [Related]
51. Clinical trial results often overstate benefits of treatment. Day M BMJ; 2007 Jun; 334(7608):1341. PubMed ID: 17599997 [No Abstract] [Full Text] [Related]
52. Go, no-go decision making for phase 3 clinical trials: ACT IV revisited. Nguyen HTN; Grogan P; Robins HI Lancet Oncol; 2017 Dec; 18(12):e708. PubMed ID: 29208432 [No Abstract] [Full Text] [Related]
53. Consequences of randomized clinical trial design decisions need to be clarified. Riddle DL J Clin Epidemiol; 2016 Sep; 77():13-14. PubMed ID: 26957108 [No Abstract] [Full Text] [Related]
54. Every effect size has its place: a commentary on the avoidance of pre-post effect sizes. Kösters M Epidemiol Psychiatr Sci; 2017 Aug; 26(4):369-370. PubMed ID: 28202092 [No Abstract] [Full Text] [Related]
55. The significance of clinical trials and the role of meta-analyses. Bartolucci A J Surg Oncol; 1999 Nov; 72(3):121-3. PubMed ID: 10562356 [No Abstract] [Full Text] [Related]
56. Patient-level and trial-level data meta-analyses. Gao Y; Li Z; Liu M; Tian J Lancet; 2024 Jul; 404(10449):243. PubMed ID: 39033008 [No Abstract] [Full Text] [Related]
57. Patient-level and trial-level data meta-analyses. Jorda A; Zeitlinger M; Jilma B; Gelbenegger G Lancet; 2024 Jul; 404(10449):242-243. PubMed ID: 39033006 [No Abstract] [Full Text] [Related]